title: Do children benefit from mass screening for neuroblastoma? Consensus Statement from the American Cancer Society Workshop on Neuroblastoma Screening.
authors.affiliation: Northwestern University Medical School, Chicago, Illinois.
authors.forename: S B
authors.initials: SB
authors.lastname: Murphy
authors.forename: S L
authors.initials: SL
authors.lastname: Cohn
authors.forename: A W
authors.initials: AW
authors.lastname: Craft
authors.forename: W G
authors.initials: WG
authors.lastname: Woods
authors.forename: T
authors.initials: T
authors.lastname: Sawada
authors.forename: R P
authors.initials: RP
authors.lastname: Castleberry
authors.forename: H L
authors.initials: HL
authors.lastname: Levy
authors.forename: P C
authors.initials: PC
authors.lastname: Prorok
authors.forename: G D
authors.initials: GD
authors.lastname: Hammond
mesh_terms: D000367:Age Factors; D005069:Evaluation Studies as Topic; D006719:Homovanillic Acid / Q000652:urine; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007564:Japan / Q000453:epidemiology; D008403:Mass Screening; D009447:Neuroblastoma / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control* / Q000652:urine; D011379:Prognosis; D015996:Survival Rate; D014642:Vanilmandelic Acid / Q000652:urine
chemical_list: D014642:Vanilmandelic Acid; D006719:Homovanillic Acid